知搜-全球专利检索

  1. 登录
  2. 注册
发明授权
CN101845441B 一种复合猪α干扰素基因及其重组载体 失效 - 权利终止

一种复合猪α干扰素基因及其重组载体
摘要：
本发明涉及一种复合猪α干扰素基因及其重组载体，属于基因工程生物制品技术领域。将新设计的复合猪α干扰素的基因序列重组到pPICZα-A载体，电转化入酵母菌感受态细胞，阳性鉴定、高拷贝酵母菌株的筛选、诱导表达。采用毕赤酵母表达系统表达外源基因，有利于猪干扰素商业化生产。该基因组表达的蛋白与酵母表达的天然干扰素相比，其表达量提高3.17倍。荧光定量PCR结果显示，用10-6mg/ml该复合猪α干扰素预处理的PK-15细胞再感染PRV，其PRVmRNA水平明显低于没经过复合猪α干扰素处理的PK-15细胞感染PRV后的PRVmRNA的水平，其PRVmRNA水平降低了37倍。
摘要（英）：

The invention relates to a composite porcine alpha-IFN gene and a recombinant vector thereof, and belongs to the technical field of genetic engineering biological products. The newly designed gene sequences of composite porcine alpha-IFN are recombined to pPICZ alpha-A vectors, and the vectors are electronically transformed into yeast competent cells; and the positive identification, and the screening and the induced expression of high copy yeast strains are carried out. A pichia pastoris expression system is used for expressing foreign genes so as to be favorable for the commercial production of porcine IFN. Compared with the natural IFN which is expressed by yeast, the expression level of the protein which is expressed by genome increases by 3.17 times. The fluorescent quantitative PCR result shows that the level of PRVmRNA after PK-15 cells treated by 10-6mg/ml of the composite porcine alpha-IFN are re-infected with PRV is obviously lower than the level of PRVmRNA after the PK-15 cells which are not treated by the composite porcine alpha-IFN are infected with the PRV, and the level of PRVmRNA decreases by 37 times.

公开/授权文献
0/0